CD27 is a TNF receptor super family
member. It is expressed on the surface of T and B cells, and its binding with CD70 provides a co-stimulatory
signal for T and B cell proliferation and for B cells producing immunoglobulins.
Treating mice with a CD27 agonist antibody effectively enhanced the antitumor
immune response for lymphoma and B16
melanoma, providing putative targets for tumor immunotherapy.
mRNA expression analysis
1. RT-PCR analysis of CD27 gene.
ThehCD27, but not mCD27,
mRNA was detected in splenocytes of the homozygous B-hCD27 mice.
Protein expression analysis
Fig 2. Splenocytes from both wild type (WT) C57BL/6 and
homozygous B-hCD27 mice were analyzed by flow cytometry. Mouse CD27+ T cells were detected in
both WT C57BL/6 and homozygous B-hCD27 mice, while human CD27+ T cells were only detected in homozygous B-hCD27 mice.
This might be due to cross-recognition of hCD27 by anti-mCD27 antibodies.
Human CD27 mAb efficacy evaluation (MC38 cell line)
3. Murinecolon cancer MC38 cells were subcutaneously implanted into heterozygous B-hCD27
mice. Mice were divided into control and treatment groups (n=5) when the tumor
size was approximately 100 mm3.
Anti-hCD27 antibody significantly inhibited tumor growth in heterozygous
B-hCD27 mice, suggesting that the B-hCD27 mouse model is an effective tool for in vivo hCD27 antibody efficacy studies. (A)
Tumor average volume ± SEM, (B) Mice average weight ± SEM.